GSA Capital Partners LLP Acquires Shares of 62,326 Celldex Therapeutics, Inc. (NASDAQ:CLDX)

GSA Capital Partners LLP purchased a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 62,326 shares of the biopharmaceutical company's stock, valued at approximately $1,131,000. GSA Capital Partners LLP owned approximately 0.09% of Celldex Therapeutics at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. KLP Kapitalforvaltning AS purchased a new position in Celldex Therapeutics during the fourth quarter worth approximately $306,000. Vanguard Group Inc. raised its position in Celldex Therapeutics by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 3,881,995 shares of the biopharmaceutical company's stock valued at $98,098,000 after purchasing an additional 12,213 shares during the period. JPMorgan Chase & Co. raised its position in Celldex Therapeutics by 103.3% in the fourth quarter. JPMorgan Chase & Co. now owns 85,545 shares of the biopharmaceutical company's stock valued at $2,162,000 after purchasing an additional 43,470 shares during the period. Headlands Technologies LLC purchased a new stake in Celldex Therapeutics in the fourth quarter valued at $81,000. Finally, Bryce Point Capital LLC purchased a new stake in Celldex Therapeutics in the fourth quarter valued at $601,000.

Analysts Set New Price Targets

A number of research firms have commented on CLDX. The Goldman Sachs Group reduced their target price on Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a research report on Friday, May 9th. Canaccord Genuity Group began coverage on Celldex Therapeutics in a report on Monday, April 28th. They issued a "buy" rating and a $64.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and issued a $50.00 price objective on shares of Celldex Therapeutics in a report on Friday, June 13th. Morgan Stanley lowered their target price on Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a research note on Friday, May 9th. Finally, UBS Group lowered their target price on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Celldex Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $50.11.

Celldex Therapeutics Stock Performance

Shares of NASDAQ:CLDX traded down $0.83 on Thursday, hitting $21.98. 783,425 shares of the company's stock were exchanged, compared to its average volume of 824,071. The firm's 50-day moving average is $21.29 and its 200 day moving average is $20.83. The company has a market capitalization of $1.46 billion, a PE ratio of -8.14 and a beta of 1.13. Celldex Therapeutics, Inc. has a 1-year low of $14.40 and a 1-year high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). The business had revenue of $0.70 million for the quarter, compared to analyst estimates of $1.08 million. Celldex Therapeutics had a negative return on equity of 23.46% and a negative net margin of 2,366.07%. On average, analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.